These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10721092)

  • 21. Pathogenesis of L-tryptophan eosinophilia myalgia syndrome.
    Sternberg EM
    Adv Exp Med Biol; 1996; 398():325-30. PubMed ID: 8906284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina.
    Sullivan EA; Kamb ML; Jones JL; Meyer P; Philen RM; Falk H; Sinks T
    Arch Intern Med; 1996 May; 156(9):973-9. PubMed ID: 8624177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eosinophilia-myalgia syndrome associated with L-tryptophan. A case report with pulmonary manifestations and review of the literature.
    André M; Canon JL; Levecque P; Dermine P; Mortier C; Leveau F
    Acta Clin Belg; 1991; 46(3):178-82. PubMed ID: 1656679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eosinophil-active cytokine from mononuclear cells cultured with L-tryptophan products: an unexpected consequence of endotoxin contamination.
    Kita H; Mayeno AN; Weyand CM; Goronzy JJ; Weiler DA; Lundy SK; Abrams JS; Gleich GJ
    J Allergy Clin Immunol; 1995 Jun; 95(6):1261-7. PubMed ID: 7797795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-tryptophan-related eosinophilia-myalgia syndrome possibly associated with a chronic B-lymphocytic leukemia.
    Böhme A; Wolter M; Hoelzer D
    Ann Hematol; 1998 Nov; 77(5):235-8. PubMed ID: 9858150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eosinophilia myalgia syndrome: absence of immunoglobulin reactivity suggests a cellular rather than humoral mechanism.
    Villanova M; De Clerck LS; Cras P; Guazzi GC; Martin JJ
    Acta Neurol Belg; 1994; 94(3):200-4. PubMed ID: 7976226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanisms.
    Brenneman DE; Page SW; Schultzberg M; Thomas FS; Zelazowski P; Burnet P; Avidor R; Sternberg EM
    J Pharmacol Exp Ther; 1993 Aug; 266(2):1029-35. PubMed ID: 8355179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of L-tryptophan and eosinophilia-myalgia syndrome.
    Roufs JB
    J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production of polyclonal antibodies against 1,1'-ethyliden bis[L-tryptophan] (EBT), a potential contaminant causing eosinophilia-myalgia syndrome (EMS).
    Kurihara N; Yanagisawa H; Jin Z; Wada O
    Toxicol Lett; 1993 Mar; 66(3):231-6. PubMed ID: 8475503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic demyelinating polyneuropathy associated with eosinophilia-myalgia syndrome.
    Freimer ML; Glass JD; Chaudhry V; Tyor WR; Cornblath DR; Griffin JW; Kuncl RW
    J Neurol Neurosurg Psychiatry; 1992 May; 55(5):352-8. PubMed ID: 1534836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Demyelinating polyneuropathy in eosinophilia-myalgia syndrome.
    Donofrio PD; Stanton C; Miller VS; Oestreich L; Lefkowitz DS; Walker FO; Ely EW
    Muscle Nerve; 1992 Jul; 15(7):796-805. PubMed ID: 1323757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case of the eosinophilia-myalgia syndrome].
    Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
    Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome.
    Cilursu AM; Goeken J; Olson RR
    Ann Rheum Dis; 1991 Nov; 50(11):817-9. PubMed ID: 1772299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.
    Takagi H; Ochoa MS; Zhou L; Helfman T; Murata H; Falanga V
    J Clin Invest; 1995 Nov; 96(5):2120-5. PubMed ID: 7593596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eosinophilia myalgia syndrome.
    Blackburn WD
    Semin Arthritis Rheum; 1997 Jun; 26(6):788-93. PubMed ID: 9213377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
    Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
    Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients.
    Kamb ML; Murphy JJ; Jones JL; Caston JC; Nederlof K; Horney LF; Swygert LA; Falk H; Kilbourne EM
    JAMA; 1992 Jan; 267(1):77-82. PubMed ID: 1727200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic immune activation in the eosinophilia-myalgia syndrome.
    McKinley KL; Harati Y; Schneider LW
    Muscle Nerve; 1993 Sep; 16(9):947-51. PubMed ID: 8355725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistent microvasculopathy in chronic eosinophilia-myalgia syndrome.
    Smith SA
    Adv Exp Med Biol; 1996; 398():359-64. PubMed ID: 8906289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.